Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.…
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
Citius Oncology (NASDAQ: CTOR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 0.5035 USD on 20 November 2026, down 64.0% over 52 weeks. Its 52-week range is 0.4910 USD to 1.830 USD: the price is 72.5% below the high and 2.5% above the low.
Its market capitalisation is 53.25M USD.
Citius Oncology reports return on equity of -55.2%.
It holds more cash than debt, a net cash position of 6.35M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.